Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: Population-based cohort study

被引：0
|
作者：
Pradhan, Richeek [1 ]
Azoulay, Laurent [1 ]
Platt, Robert W. [2 ]
Yu, Oriana H. Y. [3 ]
机构：
[1] McGill Univ, Montreal, PQ, Canada
[2] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada
[3] Jewish Gen Hosp, Lady Davis Inst, Ctr Clin Epidemiol, Montreal, PQ, Canada
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2023年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
55
引用
收藏
页码：13 / 13
页数：1
相关论文
共 50 条
  • [31] Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study
    Jong-Mi Seong
    Jong Joo Kim
    Hae Jin Kim
    Hyun Soon Sohn
    Cardiovascular Diabetology, 19
  • [32] Association of dipeptidyl peptidase-4 inhibitor and recurrent pancreatitis risk among patients with type 2 diabetes: A retrospective cohort study
    Yang, Yi-Sun
    Kornelius, Edy
    Wang, Yu-Hsun
    Lo, Shih-Chan
    Huang, Chien-Ning
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [33] Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes
    Koska, Juraj
    Sands, Michelle
    Burciu, Camelia
    Reaven, Peter
    DIABETES & VASCULAR DISEASE RESEARCH, 2015, 12 (03): : 154 - 163
  • [34] Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture
    Driessen, Johanna H. M.
    van Onzenoort, Hein A. W.
    Henry, Ronald M. A.
    Lalmohamed, Arief
    van den Bergh, Joop P.
    Neef, Cees
    Leufkens, Hubert G. M.
    de Vries, Frank
    BONE, 2014, 68 : 124 - 130
  • [35] Acute Pancreatitis in Patients with Type 2 Diabetes Mellitus Treated with Dipeptidyl Peptidase-4 Inhibitors: A Population-Based Nested Case-Control Study
    Chou, Hsin-Chun
    Chen, Wen-Wen
    Hsiao, Fei-Yuan
    DRUG SAFETY, 2014, 37 (07) : 521 - 528
  • [36] Acute Pancreatitis in Patients with Type 2 Diabetes Mellitus Treated with Dipeptidyl Peptidase-4 Inhibitors: A Population-Based Nested Case-Control Study
    Hsin-Chun Chou
    Wen-Wen Chen
    Fei-Yuan Hsiao
    Drug Safety, 2014, 37 : 521 - 528
  • [37] Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan
    Yen, Fu-Shun
    Wei, James Cheng-Chung
    Yip, Hei-Tung
    Hwu, Chii-Min
    Hou, Ming-Chih
    Hsu, Chih-Cheng
    HEPATOLOGY INTERNATIONAL, 2021, 15 (01) : 179 - 190
  • [38] Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan
    Fu-Shun Yen
    James Cheng-Chung Wei
    Hei-Tung Yip
    Chii-Min Hwu
    Ming-Chih Hou
    Chih-Cheng Hsu
    Hepatology International, 2021, 15 : 179 - 190
  • [39] Dipeptidyl peptidase-4 inhibitors and the risk of community-acquired pneumonia in patients with type 2 diabetes
    Faillie, J. -L.
    Filion, K. B.
    Patenaude, V.
    Ernst, P.
    Azoulay, L.
    DIABETES OBESITY & METABOLISM, 2015, 17 (04): : 379 - 385
  • [40] Cost Effectiveness of Dipeptidyl Peptidase-4 Inhibitors for Type 2 Diabetes
    Jinsong Geng
    Hao Yu
    Yiwei Mao
    Peng Zhang
    Yingyao Chen
    PharmacoEconomics, 2015, 33 : 581 - 597
12345